Alzamend Neuro, Inc. Common Stock
$1.89
$0.05 (+2.72%)
$1.81Day Range$1.89
Key Statistics
Market Cap
$8.88M
Shares Outstanding
4.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 15, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$1.84
Day High
$1.89
Day Low
$1.81
Volume
241.9K
VWAP
$1.86
Prev Close
$1.84
Transactions
--
Acc. Volume
--
About Alzamend Neuro, Inc. Common Stock
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
PHARMACEUTICAL PREPARATIONSSIC 28346 employees480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA, GA, 30326844-722-6333IPO Jun 15, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001677077
- Composite FIGI
- BBG00ZMXG7M8
- Share Class FIGI
- BBG00ZMXG7N7
- Ticker Root
- ALZN
- SIC Code
- 2834
About Alzamend Neuro, Inc. Common Stock (ALZN) Stock
Alzamend Neuro, Inc. Common Stock (ALZN) closed the 2026-09-18 session at $1.89, up 2.72% versus the previous close (+0.05). The stock opened at $1.84 and traded between $1.81 and $1.89 during that session. Session trading volume was 242K shares. The volume-weighted average price (VWAP) is $1.86.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Alzamend Neuro, Inc. Common Stock has a market capitalization of $8.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ALZN is listed on the XNAS exchange. The company employs approximately 6 people. Alzamend Neuro, Inc. Common Stock is headquartered in ATLANTA, GA. The recorded listing date is 2021-06-15.
On this page you can find market ALZN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.